JP2024045128A5 - - Google Patents

Info

Publication number

JP2024045128A5

JP2024045128A5 JP2023219262A JP2023219262A JP2024045128A5 JP 2024045128 A5 JP2024045128 A5 JP 2024045128A5 JP 2023219262 A JP2023219262 A JP 2023219262A JP 2023219262 A JP2023219262 A JP 2023219262A JP 2024045128 A5 JP2024045128 A5 JP 2024045128A5

Authority

JP

Japan

Prior art keywords

cell population

cells

vector

viral vector

cell

Prior art date

2023-12-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 210000004027 cell Anatomy 0.000 claims 22
• 238000000034 method Methods 0.000 claims 15
• 239000013603 viral vector Substances 0.000 claims 8
• PMATZTZNYRCHOR-JLPRAAIDSA-N (3r,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-JLPRAAIDSA-N 0.000 claims 6
• 108010019251 cyclosporin H Proteins 0.000 claims 6
• 239000013598 vector Substances 0.000 claims 6
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 210000001744 T-lymphocyte Anatomy 0.000 claims 3
• 239000002773 nucleotide Substances 0.000 claims 3
• 125000003729 nucleotide group Chemical group 0.000 claims 3
• 210000000130 stem cell Anatomy 0.000 claims 3
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
• 229960002986 dinoprostone Drugs 0.000 claims 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims 2
• 238000010361 transduction Methods 0.000 claims 2
• 230000026683 transduction Effects 0.000 claims 2
• 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
• 102100034343 Integrase Human genes 0.000 claims 1
• 108010061833 Integrases Proteins 0.000 claims 1
• 208000015439 Lysosomal storage disease Diseases 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 230000000735 allogeneic effect Effects 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 230000002950 deficient Effects 0.000 claims 1
• 230000001419 dependent effect Effects 0.000 claims 1
• -1 dimethyl prostaglandin E2 Chemical compound 0.000 claims 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims 1
• 230000012202 endocytosis Effects 0.000 claims 1
• 238000010362 genome editing Methods 0.000 claims 1
• 238000000338 in vitro Methods 0.000 claims 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
• 230000001177 retroviral effect Effects 0.000 claims 1
• 229960002930 sirolimus Drugs 0.000 claims 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
• 230000002463 transducing effect Effects 0.000 claims 1
• 238000002054 transplantation Methods 0.000 claims 1